A living tissue bank of patient-derived cell lines from high-grade brain cancer KU Leuven
Glioblastoma (GBM) is the most common and aggressive primary central nervous system malignancy with a median survival of about 15 months upon maximal standard-of-care therapy. Even though the genetic aberrations of GBM have been studied extensively, treatment options remain limited and very inefficient. To speed up the identification of alternative therapeutic approaches, in vitro studies on cancer cell lines offer a valid strategy. However, ...